Department of Haematology, Royal Infirmary, Castle Street, Glasgow, UK.
Expert Rev Hematol. 2009 Oct;2(5):499-507. doi: 10.1586/ehm.09.43.
ATryn(®) is a transgenically produced recombinant antithrombin (AT) concentrate licensed in Europe and the USA for the thromboprophylaxis of hereditary AT-deficient patients undergoing surgical procedures who are at a high risk of venous thromboembolism. It is also licensed, in the USA only, for prevention the of venous thromboembolism in association with delivery and the immediate post-partum period. ATryn is administered as a continuous intravenous infusion, with weight-adjusted loading and maintenance dosing regimens. Recombinant AT has an identical amino acid structure with minor glycosylation differences to endogenous AT. ATryn has a shorter half-life but an equivalent efficacy to that of plasma-derived AT concentrates in the prevention of venous thromboembolism in this rare distinct group with a high thrombotic risk. In addition, this recombinant product should be free from the risk of human viral or prion transmission.
依达肝素钠（®）是一种转基因生产的重组抗凝血酶（AT）浓缩物，在欧洲和美国获准用于接受手术的遗传性抗凝血酶缺乏症患者的血栓预防，这些患者存在静脉血栓栓塞的高风险。依达肝素钠也仅在美国获准用于分娩和产后即刻期间静脉血栓栓塞的预防。依达肝素钠作为连续静脉输注给药，采用体重调整的负荷剂量和维持剂量方案。重组 AT 的氨基酸结构与内源性 AT 完全相同，仅存在微小的糖基化差异。依达肝素钠的半衰期较短，但在预防该高血栓风险的罕见特定人群的静脉血栓栓塞方面，与血浆源性 AT 浓缩物的疗效相当。此外，这种重组产品应该没有感染人类病毒或朊病毒的风险。
